Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular and metabolic risks associated with PCOS

  • Review
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

Abstract

Polycystic ovary syndrome, the most common endocrine disorder of reproductive age women, is often associated with insulin resistance and associated disorders. The frequency of type 2 diabetes, hyperlipidemia, cardiac risk markers, structural vascular disease, and clinical disease events are increased in this population of women. PCOS, however, represents a broad spectrum of clinical presentations, as defined by different criteria proposed in Europe and the United States. The role of insulin resistance and hence the risk of cardiometabolic disorders may in part be determined by the definition of PCOS used. Epidemiologic studies and clinical trials support the need to identify women with PCOS to determine their risk of cardiometabolic disorders to prevent and/or treat their serious consequences.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Notes

  1. MBS defined as at least (3/8)of the following parameters:

    1. 1.

      first-degree relative with type II diabetes,

    2. 2.

      body mass index ≥30 kg/m2,

    3. 3.

      waist/hip ratio ≥0.88,

    4. 4.

      blood pressure ≥160/95 mm Hg or drug treatment for hypertension,

    5. 5.

      fasting serum triglyceride level ≥1.70 mmol/L,

    6. 6.

      high-density lipoprotein cholesterol value <1.20 mmol/L,

    7. 7.

      abnormal glucose metabolism, and

    8. 8.

      fasting insulin value ≥13.0 mU/L.

References

  1. Korhonen S (2001) Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome: a controlled, population-based study. Am J Obstet Gynecol 184:289–296

    Article  PubMed  CAS  Google Scholar 

  2. Korhonen S (2003) The androgenic sex hormone profile is an essential feature of metabolic syndrome in premenopausal women: a controlled community-based study. Fertil Steril 79:1327–1334

    Article  PubMed  Google Scholar 

  3. Asagami T, Holmes TH, Reaven G (2008) Differential effects of insulin sensitivity on androgens in obese women with polycystic ovary syndrome or normal ovulation. Metabolism 57(10):1355–1360

    Article  PubMed  CAS  Google Scholar 

  4. Amato MC, Galluzzo A, Finocchiaro S, Criscimanna A, Giordano C (2008) The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome. Clin Endocrinol (Oxf) 69:52–60

    Article  CAS  Google Scholar 

  5. Guastella E, Longo RA, Carmina E (2010) Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes. Fertil Steril 94:2197–2201

    Article  PubMed  CAS  Google Scholar 

  6. Coviello AD, Legro RS, Dunaif A (2006) Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91:492–497

    Article  PubMed  CAS  Google Scholar 

  7. Legro RS, Kunselman AR, Dodson WC, Dunaif A (1999) Prevalance and predictors of type 2 diabetes and impaired glucose tolerance in PCOS: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 84:165–169

    Article  PubMed  CAS  Google Scholar 

  8. Moran LJ, Misso ML, Wild RA, Norman RJ (2010) Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycistic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update 16:347–363

    Article  PubMed  CAS  Google Scholar 

  9. Wild RA, Rizzo M, Clifton S, Carmina E (2011) Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril 95:1073–1079

    Article  PubMed  CAS  Google Scholar 

  10. Sidhwani S, Scoccia B, Sunghay S, Stephens-Archer CN, Mazzone T, Sam S. (2011) PCOS is Associated with Atherogenic Changes in Lipoprotein Particle Number and size independent of body weight. Clin Endocrinol (Oxf) 2011 Clin Endocrinol (Oxf). 2011 Feb 15. doi: 10.1111/j.1365-2265.2011.04015.x

  11. Toulis KA, Goulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouchidou M, Tzellos TG, Makedos A, Chourdakis M, Tarlatzis BC (2011) Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 17:741–760

    Article  PubMed  CAS  Google Scholar 

  12. Escobar-Morreale HF, Luque-Ramirez M, Gonzalez F (2011) Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril 95:1048–1058

    Article  PubMed  CAS  Google Scholar 

  13. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy PF 2nd, Fitzpatrick LA (2003) Prevalence and predictors of coronary artery calcification in women with polycistic ovary syndrome. J Clin Endocrinol Metab 88:2562–2568

    Article  PubMed  CAS  Google Scholar 

  14. Luque-Ramirez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF (2007) Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. Hum Reprod 22:3197–3203

    Article  PubMed  CAS  Google Scholar 

  15. de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM (2011) PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 17:495–500

    Article  PubMed  Google Scholar 

  16. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD (2008) Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute sponsored Women’s Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 93:1276–1284

    Article  PubMed  CAS  Google Scholar 

  17. Raval AD, Hunter T, Stuckey B, Hart RJ (2011) Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev (10): CD008565. doi: 10.1002/14651858.CD008565.pub2

  18. Puurumen J, Piltonen T, Morin-Papunen L, Perheentupa A, Jarvela I, Ruokonen A, Tapaneinen JS (2011) Unfavorable hormonal, metabolic and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab 96(6):1827–1834

    Article  Google Scholar 

  19. Wild RA et al (2010) CHD Events in the WHI hormone therapy trials: does presence or absence of metabolic syndrome at baseline modify the risk? Abstract S-3 21st annual meeting of NAMS. Menopause 17:1216

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Mount Sinai School of Medicine, New York, NY, USA

    Rhoda H. Cobin

Authors
  1. Rhoda H. Cobin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rhoda H. Cobin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cobin, R.H. Cardiovascular and metabolic risks associated with PCOS. Intern Emerg Med 8 (Suppl 1), 61–64 (2013). https://doi.org/10.1007/s11739-013-0924-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-013-0924-z

Keywords

Search

Navigation